ArticleJournal of ginseng research2025
Ginsenoside Rb2 demonstrates potent antiviral activity against Zika virus infection.
Article in Journal of ginseng research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Zika virus (ZIKV) infection can result in severe neurological complications, yet no approved antiviral treatments are currently available. Ginseng, a medicinal herb extensively utilized in Asian traditional medicine, has demonstrated efficacy against various diseases, which has sparked interest in exploring its potential antiviral properties for the treatment of ZIKV. Methods: We evaluated the antiviral effects of ginsenoside Rb2 (G-Rb2) in human neuronal cell lines (SK-N-SH and CCF-STTG) and in a lethal ZIKV-infected mouse model. The antiviral efficacy was assessed using bioluminescence imaging with a NanoLuc luciferase reporter ZIKV. Results: G-Rb2 (200 μM) significantly inhibited ZIKV infection Conclusion: G-Rb2 effectively inhibits ZIKV infection both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.